Company CVAbout Cipla Ltd. 
Cipla Ltd.
Large Cap
Pharmaceuticals & Biotechnology
Cipla Limited is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
Company Coordinates
Company Details
Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel Mumbai Maharashtra : 400013
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 161.51 Cr
Number of Shares
80.76 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
12-Sep-2024
80.76
161.51
7059
2
Issued under ESOP Scheme
02-Aug-2024
80.76
161.51
6815
2
Issued under ESOP Scheme
04-Jul-2024
80.76
161.51
35106
2
Issued under ESOP Scheme
10-Jun-2024
80.75
161.50
72263
2
Issued under ESOP Scheme
16-May-2024
80.74
161.49
50768
2
Issued under ESOP Scheme
15-Apr-2024
80.74
161.48
27906
2
Issued under ESOP Scheme
15-Mar-2024
80.74
161.47
1658
2
Issued under ESOP Scheme
15-Feb-2024
80.74
161.47
5863
2
Issued under ESOP Scheme
18-Jan-2024
80.74
161.47
1899
2
Issued under ESOP Scheme
02-Jan-2024
80.74
161.47
7244
2
Issued under ESOP Scheme
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 42 Schemes (20.23%)
FIIs
Held by 958 FIIs (24.55%)
Promoter with highest holding
Yusuf Khwaja Hamied (18.69%)
Highest Public shareholder
Lici Asm Non Par (6.15%)
Individual Investors Holdings
13.82%
Board of Directors
Management
Designation
Remuneration
Y K Hamied
Chairman (Non-Executive)
2.08 cr
M K Hamied
Vice Chairman
2.1 cr
S Radhakrishnan
Non-Exec & Non-Independent Dir
2.21 cr
Ashok Sinha
Non-Exec. & Independent Dir.
94.0 lacs
Peter Mugyenyi
Non-Exec. & Independent Dir.
98.0 lacs
Adil Zainulbhai
Non-Exec. & Independent Dir.
66.0 lacs
Punita Lal
Non-Exec. & Independent Dir.
65.0 lacs
Samina Hamied
Executive Vice Chairperson
9.25 cr
Umang Vohra
Managing Director & Global CEO
17.49 cr
Rajendra Chopra
Company Sec. & Compli. Officer
0
Robert A Stewart
Independent Director
1.05 cr
P R Ramesh
Independent Director
68.0 lacs
Mandar Purushottam Vaidya
Independent Director
43.0 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals
11,968.40
91.76%
Other Operating Income
170.90
1.31%
Export Incentives
155.27
1.19%
Pharmaceuticals
Pharmaceuticals
Other Operating Income
Other Operating Income
Export Incentives
Export Incentives
Stock DNARevenue and Profits:
Net Sales:
7,589 Cr
(Quarterly Results - Sep 2025)
Net Profit:
1,351 Cr
Pharmaceuticals & Biotechnology
INR 122,604 Cr (Large Cap)
23.00
34
0.00%
-0.24
16.53%
3.73
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
